Literature DB >> 8279170

Recurrent angioedema and urticaria.

P C Bishop1, J J Wisnieski, J Christensen.   

Abstract

The case reported here illustrates the life-threatening aspects of angioedema and the need to thoroughly investigate the possible causes of this clinical finding. As discussed, the causes of angioedema are numerous. Commonly implicated in drug-induced angioedema are antihypertensive ACE inhibitor drugs, as was originally thought with this patient. Because of her skin lesions and macrocytic anemia, further studies were done. These studies led to a diagnosis of hypocomplementemic urticarial vasculitis syndrome, an uncommon to rare form of acquired angioedema, urticarial vasculitis, arthritis, and obstructive airway disease associated with the production of autoantibodies to C1q. It is an autoimmune disorder related to but separate from SLE.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8279170      PMCID: PMC1022365     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  21 in total

1.  Hypocomplementemia with cutaneous vasculitis and arthritis. Possible immune complex syndrome.

Authors:  F C McDuffie; W M Sams; J E Maldonado; P H Andreini; D L Conn; E A Samayoa
Journal:  Mayo Clin Proc       Date:  1973-05       Impact factor: 7.616

2.  Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor.

Authors:  J E Gadek; S W Hosea; J A Gelfand; M Santaella; M Wickerhauser; D C Triantaphyllopoulos; M M Frank
Journal:  N Engl J Med       Date:  1980-03-06       Impact factor: 91.245

3.  Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition.

Authors:  E E Slater; D D Merrill; H A Guess; P J Roylance; W D Cooper; W H Inman; P W Ewan
Journal:  JAMA       Date:  1988-08-19       Impact factor: 56.272

Review 4.  Hypocomplementemic urticarial vasculitis: association with chronic obstructive pulmonary disease.

Authors:  H R Schwartz; F C McDuffie; L F Black; A L Schroeter; D L Conn
Journal:  Mayo Clin Proc       Date:  1982-04       Impact factor: 7.616

Review 5.  Angioedema: 5 years' experience, with a review of the disorder's presentation and treatment.

Authors:  C A Megerian; J E Arnold; M Berger
Journal:  Laryngoscope       Date:  1992-03       Impact factor: 3.325

6.  C1q deficiency associated with urticarial-like lesions and cutaneous vasculitis.

Authors:  R J Marder; R Rent; E Y Choi; H Gewurz
Journal:  Am J Med       Date:  1976-10       Impact factor: 4.965

7.  Acquired C1 esterase inhibitor deficiency and angioedema: a review.

Authors:  J A Gelfand; G R Boss; C L Conley; R Reinhart; M M Frank
Journal:  Medicine (Baltimore)       Date:  1979-07       Impact factor: 1.889

8.  Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency.

Authors:  K Bork; G Witzke
Journal:  J Allergy Clin Immunol       Date:  1989-03       Impact factor: 10.793

9.  A hypocomplementemic vasculitic urticarial syndrome. Report of four new cases and definition of the disease.

Authors:  C R Zeiss; F X Burch; R J Marder; N L Furey; F R Schmid; H Gewurz
Journal:  Am J Med       Date:  1980-06       Impact factor: 4.965

10.  Angioedema induced by a peptide derived from complement component C2.

Authors:  C J Strang; S Cholin; J Spragg; A E Davis; E E Schneeberger; V H Donaldson; F S Rosen
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  3 in total

Review 1.  ACE inhibitor-induced angioedema. Incidence, prevention and management.

Authors:  W Vleeming; J G van Amsterdam; B H Stricker; D J de Wildt
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

Review 2.  Urticarial vasculitis.

Authors:  Joe Venzor; Wai L Lee; David P Huston
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

Review 3.  Urticarial vasculitis.

Authors:  Natalie A Brown; John D Carter
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.